4-(azetidin-3-yloxy)pyridine 2,2-trifluoroethanoate | 1251999-13-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(azetidin-3-yloxy)pyridine 2,2-trifluoroethanoate
• 英文别名: 4-(azetidin-3-yloxy)pyridine；4-(azetidin-3-yloxy)pyridin
• CAS: 1251999-13-9
• 化学式: C₈H₁₀N₂O
• mdl: MFCD14583136
• 分子量: 150.18
• InChiKey: RLQYIYTUKIVZKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  10-chloro-5,6,8,9-tetrahydro-1,4,7,10a-tetraaza-cyclohepta[f]indene-7-carboxylic acid tert-butyl ester 、 4-(azetidin-3-yloxy)pyridine 2,2-trifluoroethanoate 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT2C agonists for the treatment of metabolic disorders

  摘要：

  The discovery of a novel series of 5-HT2C agonists based on a tricyclic pyrazolopyrimidine scaffold is described. Compounds with good levels of in vitro potency and moderate to good levels of selectivity with respect to the 5-HT2A and 5-HT2B receptors were identified. One of the analogues (7g) was found to be efficacious in a sub-chronic weight loss model. A key limitation of the series of compounds was that they were found to be potent inhibitors of the hERG ion channel. Some compounds, bearing polar side chains were identified which showed a much reduced hERG liability however these compounds were sub-optimal in terms of their in vitro potency or selectivity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.089
• 作为产物：
  描述：

  3-(吡啶-4-基氧基)氮杂丁烷-1-羧酸叔丁酯 、 三氟乙酸 在 silica gel 、 chloroform methanol 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 5.0h， 以to obtain 4-(azetidin-3-yloxy)pyridine (268 mg)的产率得到4-(azetidin-3-yloxy)pyridine 2,2-trifluoroethanoate
  参考文献：
  名称：

  Guanidine compound

  摘要：

  [问题]本发明提供了一种化合物，该化合物可用作制药组合物的活性成分，特别是用于预防和/或治疗VAP-1相关疾病的制药组合物。 [解决方案]本发明人对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的该化合物或其盐具有出色的VAP-1抑制活性，并且对于预防和/或治疗VAP-1相关疾病，特别是糖尿病肾病或糖尿病黄斑水肿非常有用，从而完成了本发明。此外，本发明涉及一种制药组合物，特别是用于预防和/或治疗VAP-1相关疾病的制药组合物，其包括本发明的该化合物或其盐以及赋形剂。

  公开号：

  US09051283B2

文献信息

• Guanidine compound
  申请人：Astellas Pharma Inc.

  公开号：US09051283B2

  公开（公告）日：2015-06-09

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

  [问题]本发明提供了一种化合物，该化合物可用作制药组合物的活性成分，特别是用于预防和/或治疗VAP-1相关疾病的制药组合物。 [解决方案]本发明人对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的该化合物或其盐具有出色的VAP-1抑制活性，并且对于预防和/或治疗VAP-1相关疾病，特别是糖尿病肾病或糖尿病黄斑水肿非常有用，从而完成了本发明。此外，本发明涉及一种制药组合物，特别是用于预防和/或治疗VAP-1相关疾病的制药组合物，其包括本发明的该化合物或其盐以及赋形剂。
• PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES
  申请人：H. Lundbeck A/S

  公开号：EP3865484A1

  公开（公告）日：2021-08-18

  The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.

  本发明涉及 PDE9 抑制剂及其用于治疗良性前列腺增生症和镰状细胞病的用途。
• PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
  申请人：H. LUNDBECK A/S

  公开号：US10513524B2

  公开（公告）日：2019-12-24

  The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.

  本发明涉及 PDE9 抑制剂及其用于治疗良性前列腺增生症和镰状细胞病的用途。
• PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES
  申请人：H. Lundbeck A/S

  公开号：EP3303339B1

  公开（公告）日：2021-01-13
• ENZYME INHIBITORS
  申请人：Kalvista Pharmaceuticals Limited

  公开号：EP4017850A1

  公开（公告）日：2022-06-29